Recent advancements in Continuous Manufacturing (CM), artificial intelligence and machine learning (AI/ML) and anticipated regulatory shifts—such as the potential waiver of Phase III clinical trials—have paved the way for a new biosimilar development and manufacturing company. Ardent Biopharma is seizing this opportunity to redefine cost efficiency in the production of monoclonal antibodies (mAbs) and other therapeutic proteins.

Leveraging these innovations, we aim to deliver biosimilars below 20% of the originator price, significantly improving global affordability and accessibility to life-saving or life-enhancing biologic therapies. Ardent aspires to become a cost leader in the biosimilars industry. Both first and second wave biosimilars will be developed. 

Development will be done in close collaboration with our partners until we can operate from a proprietary facility in The Netherlands. Future product M&S will be realized through specialized parties per region.

Ardent Biopharma

Org chart

Teams

Offices

Ardent Biopharma

Org chart

Teams

Offices

Related companies